頭頚部癌患者に対する動注化学療法と放射線療法の併用による術前治療 カルボプラチンとシスプラチンの副作用の比較

Abstract

Adverse effects of carboplatin (CBDCA) was compared with that of cisplatin (CDDP) in the course of preoperative treatment combined with aintraarterial chemotherapy and radiotherapy for head and neck cancers. The CBDCA group consisted of 12 previously untreated patients who received both intraarterial chemotherapy with CBDCA (80 mg/m2, on days 1 and 8) and peplomycin (PEP: 5 mg/body/day, from day 1 to 5 and day 8 to 12) and 60Co-radiotherapy (total to 20 Gy) before surgery. For controls, seven patients, who had also received both intraarterial chemotherapy with CDDP (20 mg/m2, on days 1 and 8) and PEP (5 mg/body/day, from day 1 to 5 and day 8 to 12) and 60Co-radiotherapy (total to 20-30 Gy) preoperatively, were examined (CDDP group).Counts of white blood cells (WBC), red blood cells (RBC), and platlets (PLAT.) for myelosuppression, blood urea nitrogen concentration (BUN), urinary N-acetyl-β-D-glucosaminidase activity (NAG) and β2-microglobulin concentration (BMG) for nephrotoxicity, and some clinical signs (nausea or vomiting, stomatitis, and alopecia) were evaluated. The above clinical examinations were made several times before, during, and after chemo-and radio-therapy. All the above data except for the clinical signs were within the normal range through the present therapeutic courses in the CBDCA group. On the contrary, WBC, NAG, and BMG increased significantly on the next day of drug administration in the CDDP group.Alopecia was significantly severer in the CDDP group than in the CBDCA group. It was considered that the adverse effects of CBDCA were slighter than those of CDDP in the present dosage.